

Chinese Red Yeast Rice Inhibition of Prostate Tumor Growth in SCID Mice

Mee Young Hong¹, Susanne Henning¹, Aune Moro¹, Navindra P. Seeram², Yanjun Zhang¹, and David Heber¹

Abstract

Prostate cancer is a slowly developing but very common cancer in males that may be amenable to preventive strategies that are not toxic. Chinese red yeast rice (RYR), a food herb made by fermenting *Monascus purpureus* Went yeast on white rice, contains a mixture of eight different monacolins that inhibit cholesterol synthesis in addition to red pigments with antioxidant properties. Monacolin K is identical to lovastatin (LV), but LV unlike RYR can be used in individuals intolerant to statins due to muscle pain. Both LV and RYR inhibit *de novo* cholesterol synthesis, which is critical to the growth of tumor cells. Long-term use of statin drugs has been associated with a reduced risk of prostate cancer. We have previously shown that RYR inhibited androgen-dependent and androgen receptor-overexpressing androgen-independent prostate cancer cell proliferation *in vitro*. This study was designed to determine whether RYR and LV inhibit prostate tumor growth in SCID mice. RYR significantly reduced tumor volumes of androgen-dependent and androgen-independent prostate xenograft tumors compared with animals receiving vehicle alone ($P < 0.05$). Inhibition by RYR was greater than that observed with LV at the dose found in RYR, showing that other compounds in RYR contributed to the antiproliferative effect. There was a significant correlation of tumor volume to serum cholesterol ($P < 0.001$). RYR decreased gene expression of androgen synthesizing enzymes (HSD3B2, AKR1C3, and SRD5A1) in both type of tumors ($P < 0.05$). Clinical studies of RYR for prostate cancer prevention in the increasing population of men undergoing active surveillance should be considered. *Cancer Prev Res*; 4(4); 608–15. ©2011 AACR.

Introduction

Prostate cancer is the second most common cause of cancer death in men in the United States today (1). It is estimated that 217,730 new cases occurred and 32,050 men will die of prostate cancer in 2010 (1). Early-stage prostate cancer is androgen-dependent and can be effectively treated by androgen ablation therapy, radiation, and/or surgery (2–7). However, prostate tumors relapse and advance to an androgen-independent state where they progress, in the absence of circulating testosterone, leading to metastasis and death (2–7). Reducing the rate of emergence of androgen-independent cells in late stages of

advanced prostate cancer is critical to reducing overall mortality from prostate cancer.

Red yeast rice (RYR) is a traditional food spice consumed throughout Asia (8–11) and its food and medicinal value is believed to date back more than a thousand years. RYR contains a family of monacolins, one of which is monacolin K, which is identical to lovastatin (LV), and has the ability to inhibit cholesterol synthesis and lower plasma cholesterol levels (12, 13). Our group showed that the administration of a dose of 2,400 mg/day of RYR, containing 0.4% monacolins by weight, to hypercholesterolemic participants resulted in significant reduction of total cholesterol and low-density lipoprotein (LDL) cholesterol with approximate bioequivalence to 20 mg of LV, suggesting that other substances in RYR had biological activity (14).

A recent case-control study (15) reported that hypercholesterolemia was associated with a 50% increase in the risk of prostate cancer. In clinical studies, statin drug use was protective against prostate cancer (16–24) although the mechanisms of this effect have not been established. Recently, we showed that RYR could inhibit *in vitro* proliferation of both LNCaP human prostate cancer cells and LNCaP-AR cells which are androgen-independent and overexpress the androgen receptor (AR; ref. 25).

Androgen-independent cells synthesize testosterone intracellularly via several enzymes which support tumor growth in the absence of circulating androgens (26–30).

Authors' Affiliations: ¹Center for Human Nutrition, David Geffen School of Medicine, University of California, Los Angeles, California and ²Department of Biomedical and Pharmaceutical Sciences, The University of Rhode Island, Kingston, Rhode Island

Note: Supplementary data for this article are available at Cancer Prevention Research Online (<http://cancerprevres.aacrjournals.org/>).

Current address for M.Y. Hong: School of Exercise and Nutritional Sciences, San Diego State University, San Diego, CA 92182.

Corresponding Author: David Heber, Center for Human Nutrition, 900 Veteran Ave. Room 1-2-217, University of California at Los Angeles, Los Angeles, CA 90095. Phone: 310-206-1987; Fax: 310-206-5264. E-mail: dheber@mednet.ucla.edu

doi: 10.1158/1940-6207.CAPR-10-0219

©2011 American Association for Cancer Research.

3 β -Hydroxysteroid dehydrogenase type 2 (HSD3B2) catalyzes the conversion of dehydroepiandrosterone to androstenedione (26, 27). In addition, aldo-keto reductase family 1, member C3 (AKR1C3) converts androstenedione to testosterone, and increased amounts of AKR1C3 have been shown in prostate cancer cells (28). Testosterone is converted to dihydrotestosterone (DHT) by steroid 5 α -reductase type 1 (SRD5A1; ref. 29). Because DHT has a greater affinity for AR than testosterone, it has been proposed that DHT is critical to prostate cancer development (27). Inhibitors of SRD5A1, such as finasteride, reduce prostate size and have been shown to reduce the development of prostate cancers by 25% but increase the number of advanced cancers found (31, 32). Therefore, androgen synthesis enzymes may be critical for the development of androgen-independent prostate cancer.

This study examined the effects of RYR on the growth of androgen-dependent LNCaP and androgen-independent LNCaP-AR human prostate cancer xenografts in severe combined immunodeficient (SCID) mice as well as the relationship of circulating cholesterol to tumor growth and the effects of treatment with RYR on gene expression of androgen-synthesizing enzymes.

Materials and Methods

SCID animals and diets

Sixty male SCID mice, ages 5 weeks, were purchased from Taconic Farms Inc. and housed 5 mice per cage in a pathogen-free environment. After acclimation, all mice were implanted in the shoulder with androgen-dependent

LNCaP or androgen-independent LNCaP-AR human prostate cancer cells (8×10^6) subcutaneously ($n = 30$ each). LNCaP cells were purchased from the American Type Culture Collection and lower passages (4–6 passages) of cells were used. LNCaP-AR cells were provided from Dr. Charles Sawyers' lab (University of California, Los Angeles, CA) 3 months prior to the experiments. LNCaP cells are androgen-dependent prostate cancer cells, whereas LNCaP-AR cells are androgen-independent prostate cancer cells with AR overexpression. The LNCaP and LNCaP-AR cells were authenticated by Pathogen PCR Testing in Division of Laboratory Animal Medicine (DLAM Lab, University of California, Los Angeles, CA) right before the xenograft study.

In each xenograft tumor group (LNCaP and LNCaP-AR), 10 mice were assigned to each diet treatment (control, LV, or RYR diet). The control diet was a modified AIN 93G diet (Dyets) with 20% fat (20% soybean oil). The RYR diet contained 5% of RYR powder (Botanica Bioscience) with the modified AIN93G diet. For LV diet, LV (Mylan Pharmaceuticals Inc.) was added to the control diet in an amount equivalent to that in the 5% RYR diet. The amounts present in the LV diet and 5% RYR diet were found to be nearly identical after determination by high-performance liquid chromatography (HPLC; Fig. 1). Statin standard was used as a positive control to identify the statin (monacolin K) component in RYR by using HPLC (Fig. 1).

Animal weight, food intake, and tumor volume were measured weekly. The tumor volume was calculated by the formula: length \times width \times height \times 0.5236 (ref. 33). At sacrifice, primary tumors were excised and blood was




Figure 1. HPLC chromatograms of monacolin K in LV diet (A) and 5% RYR diet (B). The amounts of LV were very similar in both diets.

collected through cardiac puncture. The animal protocol was approved by Animal Care Committee of the University of California, Los Angeles.

Serum cholesterol and PSA

Serum cholesterol concentrations were determined by cholesterol enzymatic methods by using a cholesterol standard (StanBio). Serum prostate-specific antigen (PSA) was measured with a PSA ELISA kit (Diagnostic Systems Laboratories) according to the manufacturer's protocol.

In situ cell proliferation and apoptosis

Paraformaldehyde-fixed and paraffin-embedded tumor tissues were used to determine *in situ* cell proliferation and apoptosis analysis. Proliferating cells were detected by using monoclonal Ki-67 antibody (BD Biosciences; refs. 34, 35). Total number of cells and stained proliferating cells were counted in 2 subsquares in a 4×4 grid in 10 microscopic areas. Data are expressed as proliferation index (%), which was calculated by the formula: (no. of proliferating cells in one grid/total number of cells in one grid) \times 100. Apoptosis assay was based on terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (Millipore; ref. 34). Apoptotic cells were counted in 15 microscopic fields and data are expressed in number of apoptotic cells/field.

RNA extraction and reverse transcription

Total RNA was extracted by using TRIZOL reagent (Invitrogen) and quantified by measuring the absorbance at 260 nm with a Gene Quant Spectrophotometer (Amersham-Pharmacia Biotech). Reverse transcription was performed on 3 μ g of RNA by using oligo(dT)₁₂₋₁₈ primers (Invitrogen) with SuperScript III reverse transcriptase (Invitrogen) according to the manufacturer's instructions.

Quantitative real-time PCR

Gene expressions were determined by Taqman Universal PCR master mix and primers (Applied Biosystems) by quantitative real-time PCR, using the ABI 7900 HT Sequence Detector (Applied Biosystems; ref. 36). The transcription levels of target genes were normalized to r18S expression. Every set of reverse transcription reactions contains a reverse transcription negative control (no RNA thus no PCR products) to confirm that no contamination or anomaly has occurred.

Statistics

Data were analyzed by 1-way ANOVA followed by Student-Newman-Keuls multiple comparison with GraphPad PRISM 3.0 (GraphPad Software) in separate androgen-dependent and -independent SCID sets. The comparison between LNCaP and LNCaP-AR were done




Figure 2. A, RYR effects on SCID tumor volume. RYR-fed mice significantly reduced androgen-dependent and -independent tumor compared with control diet-fed mice. B, RYR effects on *in situ* cell proliferation. Proliferation index was lower in RYR group in both androgen-dependent and -independent SCID tumors. Values are mean \pm SE. *, significantly different from control at $P < 0.05$.

by using *t* test. The relationship between tumor volume and serum cholesterol levels was analyzed by correlation and a linear regression model.

Results

SCID Tumor volume

RYS significantly reduced androgen-dependent and -independent tumor volumes compared with control by 54% and 41%, respectively ($P < 0.05$; Fig. 2A). LV also decreased tumor volume by 32% ($P < 0.05$) but only in androgen-dependent SCID animals, and to a lesser degree than those receiving RYS (Fig. 2A).

In situ cell proliferation and apoptosis

Proliferation index was lower in the RYS group in both androgen-dependent and -independent SCID tumors by 32% and 47% ($P < 0.05$; Fig. 2B). There was no significant effect of RYS or LV on apoptosis (data not shown).

Serum PSA

PSA is a risk marker of prostate cancer and is often elevated in the presence of prostate cancer. RYS decreased serum PSA levels compared with control in both LNCaP- and LNCaP-AR-injected SCID animals ($P < 0.05$; Fig. 3).

Serum cholesterol and HMGCR gene expression

RYS decreased serum cholesterol levels by 20% in animals with androgen-dependent tumors, and 30% in animals with androgen-independent tumors ($P < 0.05$; Fig. 4A).

In animals treated with the LV diet, serum cholesterol levels declined by 10% in animals with androgen-dependent tumors, but not in those with androgen-independent tumors ($P < 0.05$; Fig. 4A). The RYS diet downregulated 3-hydroxy-3-methyl-glutaryl CoA reductase (HMGCR) gene expression by 60% in animals with androgen-dependent tumors and 40% in animals with androgen-independent tumors ($P < 0.05$; Fig. 4B). In contrast, LV-treated animals had a 4-fold increase in HMGCR gene expression compared with animals receiving the control diet (Fig. 4B). There was

a strong positive correlation between tumor volume and serum cholesterol levels ($R^2 = 0.6571$, $P < 0.001$; Fig. 5).

Gene expression of androgen synthesizing enzymes and androgen receptor

In RYS-fed animals, HSD3B2, AKR1C3, and SRD5A1 gene expression was downregulated more than 3-fold in LNCaP tumors, and more than 2-fold in LNCaP-AR tumors ($P < 0.05$; Fig. 6A–C). The RYS diet also decreased AR expression more than 2-fold in androgen-independent SCID tumors ($P < 0.05$). The transcription levels of HSD3B2, AKR1C3, and SRD5A1 and AR were higher in androgen-independent tumors than androgen-dependent tumors ($P < 0.05$; Figs. 6 and 7; Supplementary Data).

Discussion

Androgens are critical to prostate cancer development and to normal development, proliferation, and differentiation of prostate epithelial cells (2, 3). Androgen deprivation therapy is used after failure of primary prostate cancer, but the emergence of androgen-independent prostate cancer often occurs. Although cholesterol synthesis is necessary for testosterone synthesis (30), there is no convincing evidence in humans that reducing cholesterol biosynthesis affects circulating testosterone levels (37). Cholesterol-rich membranes, generally referred to as "lipid rafts," exhibit a liquid-ordered structure and are insoluble in nonionic detergents. Lipid rafts sequester and exclude certain types of signaling proteins and are thought to act as membrane platforms for signal transduction. The depletion of cholesterol from the lipid raft could inhibit prostate tumor xenograft growth (38). On the contrary, cholesterol is a required intermediate for tumor cell growth, and reduction of circulating cholesterol levels may influence the risk of progression and biology of prostate cancer (39, 40). Although we and others (38) have seen a correlation between xenograft size and circulating cholesterol levels, further research is needed to clarify which of these mechanisms are most likely involved in tumor growth inhibition.




Figure 3. RYS effects on PSA levels. RYS administration reduced serum PSA levels compared with control in both types of SCID mice. Values are mean \pm SE. *, significantly different from control at $P < 0.05$.




Figure 4. A, RYR effects on cholesterol levels. RYR reduced serum cholesterol levels more than 15% of control in androgen-dependent and -independent SCID mice. B, RYR effects on HMGR gene expression. RYR downregulated HMGR gene expression in both types of xenografted tumors. In contrast, lovastatin drug increased HMGR gene expression in LNCaP xenograft animal. Values are mean \pm SE. *, significantly different from control at $P < 0.05$.

LNCaP tumors are extremely hematogenous, unlike human prostate cancer and most other xenograft models. Consequently, bioavailability of the active ingredient(s) in RYR with respect to the tumor is likely to be higher than that in the clinical situation. Therefore, it is possible that significant effects on intratumoral cholesterol might be achieved.




Figure 5. Correlation between tumor volume and serum cholesterol levels. As tumors were getting bigger, serum cholesterol increased, or vice versa ($R^2 = 0.6571$, $P < 0.001$). All data were included.

The mechanisms by which prostatic tissue maintains tissue androgens may include metabolism of adrenal androgens or *de novo* synthesis from cholesterol (41, 42). This study verified that higher cholesterol levels were strongly correlated with larger prostate tumors. RYR downregulated enzymes involved in androgen synthesis (HSD3B2, AKR1C3, and SRD5A1) and reduced cholesterol levels. RYR may decrease androgen synthesis by reducing the precursor (i.e., cholesterol) of androgen via the inhibition of *de novo* cholesterol synthesis and downregulation of androgen synthesizing enzyme genes. In patients undergoing androgen deprivation therapy to treat prostate cancer, RYR could delay or reduce disease progression through effects on residual androgen production via reduction of the precursor of the androgen and downregulating gene expression of androgen synthesizing enzymes.

Androgen signaling occurs via intracellular AR (2, 3, 43). The AR has been implicated in the development and progression of recurrent prostate cancer and its expression is frequently upregulated in androgen-independent prostate cancer (44–46). This enhances the response to circulating androgens and those synthesized in the prostate cancer cell. This upregulation of the AR in androgen-independent tumors was consistent with our findings in which RYR downregulated AR transcription levels in the animals with androgen-independent tumors. Therefore, RYR may be particularly helpful in the subgroup of patients with androgen-independent prostate cancer and AR upregulation.

Figure 6. RYR effects on gene expression involved in androgen synthesis. RYR-fed animals downregulated HSD3B2 (A), AKR1C3 (B), and SRD5A1 (C) gene expression by more than 3- and 2-fold in LNCaP and LNCaP-AR SCID tumors. Values are mean \pm SE. *, significantly different from control at $P < 0.05$.





Figure 7. RYR effects on gene expression of AR. RYR diet also decreased AR expression by more than 2-fold in androgen-independent SCID tumors. Values are mean \pm SE. *, significantly different from control at $P < 0.05$.

De novo cholesterol synthesis may be a key target for the prevention of the emergence of prostate cancer. Much convincing evidence indicates that tumors undergo deregulated cholesterol synthesis mainly at the critical rate-controlling juncture (i.e., the reaction catalyzed by HMGCR). The mevalonate component of the cholesterol biosynthesis pathway plays a key role in controlling cell proliferation by generating prenyl intermediates, particularly farnesyl and geranyl-geranyl moieties (47–49). These isoprenoids covalently modify, and thus modulate, the biological activity of signal-transducing proteins, such as G-protein signaling. Further studies are needed to determine the effects of RYR on isoprenoid metabolism and related signaling.

We have previously shown the anticancer properties of RYR in human prostate cancer cell lines (25). The *in vitro* effects showed that RYR exhibited stronger inhibition of tumor cell growth compared with LV treatment in human androgen-dependent and -independent prostate cancer cells (25). The results are extended in the current *in vivo*

xenograft study. It is also interesting that LV administration enhanced HMGCR gene expression in androgen-dependent tumors but RYR downregulated the transcription levels in both types of tumor. Upregulation of LV on HMGCR has been reported as a feedback mechanism of lowering cholesterol. RYR contains other bioactive components such as pigments, sterols, isoflavones, and tannins. It is possible that the nonstatin ingredients in RYR may affect the different direction of response versus LV treatment. The advantage of using RYR over LV, which is a drug, is that RYR reduced tumor volume, PSA levels, and cholesterol levels without elevation of gene expression related to HMGCR, androgen synthesis, and inflammation. Moreover, RYR showed anticancer effects in both androgen-dependent and -independent prostate tumors whereas effects of LV were observed mainly in androgen-dependent SCID prostate tumors.

RYR contains red pigments and statin, and our previous experiment (36) showed that the pigments also show anticancer effects in cancer cells. Therefore, a matrix with other structural analogs and other substances including pigments was able to inhibit prostate tumor growth. Although our previous studies clearly showed that there are other factors beyond monacolin K mediating some of the effects of RYR, further studies are needed to determine the effects of other active components in RYR, including sterols, isoflavones, and tannins, on prostate cancer growth.

The amount of RYR typically used in clinical trials is 1,200 to 2,400 mg/day of RYR containing approximately 10 mg total monacolins, half of which is monacolin K.

This raises a question about function of the other monacolins and non-monacolin compounds in the products, as the monacolin K content is lower than the low end of what is usually considered effective for LV (10–80 mg/day). A meta-analysis published in 2006 cited 93 published, controlled clinical trials—91 published in Chinese. Compared

with placebo results, total cholesterol decreased by 35 mg/dL, LDL cholesterol decreased by 28 mg/dL, triglycerides decreased by 35 mg/dL, and high-density lipoprotein (HDL) cholesterol increased by 6 mg/dL (50). Of the clinical trials reviewed in the meta-analysis, the only study conducted in the United States was a randomized, placebo-controlled, double-blind study of subjects with primary hyperlipidemia (LDL > 160 mg/dL). At the end of 12 weeks, it reported changes compared with placebo of –35, –33, –13, and 0 mg/dL for total cholesterol, LDL, triglycerides, and HDL, respectively (14). Although RYR has shown inhibition of androgen-dependent and -independent prostate tumors in our studies, it is also likely to be better tolerated than statin drugs. In a recent study (51), patients experiencing myalgias, gastrointestinal intolerance, or elevated liver function tests with lipid-lowering drugs were able to tolerate RYR without any side effects. On the basis of our basic research and clinical observations of RYR in lipid-lowering trials, it is our view that clinical studies of RYR for prostate cancer prevention in men undergoing active surveillance should be considered.

Acknowledgments

We thank Dr. Simin Liu for allowing us to use his real-time PCR equipment.

Grant Support

This study was funded by UCLA/NCI Clinical Nutrition Research Unit Grant CA 42710 and by Grant W81XWH-07-1-0158 from Department of Defense (M.Y. Hong).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received August 30, 2010; revised December 15, 2010; accepted January 14, 2011; published OnlineFirst January 28, 2011.

References

1. American Cancer Society, Cancer facts and figures 2010. Available from: www.cancer.org.
2. Attard G, Sarker D, Reid A, Mollife R, Parker C, de Bono JS. Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. *Br J Cancer* 2006;95:767–74.
3. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. *Nat Med* 2004;10:33–9.
4. Kokontis JM, Hay N, Liao S. Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. *Mol Endocrinol* 1998;12:941–53.
5. Zhang L, Johnson M, Le KH, Sato M, Ilagan R, Iyer M, et al. Interrogating androgen receptor function in recurrent prostate cancer. *Cancer Res* 2003;63:4552–60.
6. Jariwala U, Prescott J, Jia L, Barski A, Pregizer S, Cogan JP, et al. Identification of novel androgen receptor target genes in prostate cancer. *Mol Cancer* 2007;6:39–53.
7. Kim D, Gregory CW, French FS, Smith GJ, Mohler JL. Androgen receptor expression and cellular proliferation during transition from androgen-dependent to recurrent growth after castration in the CWR22 prostate cancer xenograft. *Am J Pathol* 2002;160:219–26.
8. Ma J, Li Y, Ye Q, Li J, Hua Y, Ju D, et al. Constituents of red yeast rice, a traditional Chinese food and medicine. *J Agric Food Chem* 2000;48:5220–5.
9. Wang HL, Fang SL. Indigenous fermented foods of non-western origin. In: Hesselstine CW, Wang HL, editors. *Lubrecht & Cramer Ltd., Port Jervis, NY. Mycologica Memoirs*; 1986. p. 317–44.
10. Simg R-H. "Tien-Kung K'ai-Wu" Chinese technology in the seventeenth century. Pennsylvania State University Press, University Park; 1996. p. 292–4.
11. Stuart MD. Chinese material medica: vegetable kingdom. Taipei, Republic of China: Southern Materials Center; 1979.
12. Li Z, Seeram NP, Lee R, Thames G, Minutti C, Wang HJ, et al. Plasma clearance of lovastatin versus Chinese red yeast rice in healthy volunteers. *J Altern Complement Med* 2005;11:1031–8.
13. Heber D, Lembertas A, Lu Q-Y, Bowerman S, Go VLW. An analysis of nice proprietary Chinese Red Yeast Rice dietary supplements: implications of variability in chemical profile and contents. *J Altern Complement Med* 2001;7:133–9.
14. Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, Go VL. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. *Am J Clin Nutr* 1999;69:231–6.

15. Bravi F, Scotti L, Bosetti C, Talamini R, Negri E, Montella M, et al. Self-reported history of hypercholesterolaemia and gallstones and the risk of prostate cancer. *Ann Oncol* 2006;17:1014–7.
16. Cyrus-David MS, Weinberg A, Thompson T, Kadmon D. The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. *J Urol* 2005;173:1923–5.
17. Shannon J, Tewoderos S, Garzotto M, Beer TM, Derenick R, Palma A, et al. Statins and prostate cancer risk: a case-control study. *Am J Epidemiol* 2005;162:318–25.
18. Moyad MA, Merrick GS, Butler WM, Wallner KE, Galbreath RW, Kurko B, et al. Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. *Urology* 2005;66:1150–4.
19. Gutt R, Toniaar N, Kunnavaakkam R, Karrison T, Weichselbaum RR, Liauw SL. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. *J Clin Oncol* 2010;28:2653–9.
20. Katz MS, Carroll PR, Cowan JE, Chan JM, D'Amico AV. Association of statin and nonsteroidal anti-inflammatory drug use with prostate cancer outcomes: results from CaPSURE. *BJU Int* 2010;106:627–32.
21. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. *Nat Rev Cancer* 2005;5:930–42.
22. Moorman PG, Hamilton RJ. Statins and cancer risk: what do we know and where do we go from here? *Epidemiology* 2007;18:194–6.
23. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zaubler AG, Shapiro S. Statin use and the risk of breast and prostate cancer. *Epidemiology* 2002;13:262–7.
24. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC, et al. Statin drugs and risk of advanced prostate cancer. *J Natl Cancer Inst* 2006;98:1819–25.
25. Hong MY, Seeram NP, Zhang Y, Heber D. Chinese red yeast rice versus lovastatin effects on prostate cancer cells with and without androgen receptor overexpression. *J Med Food* 2008;11:657–66.
26. Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, et al. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. *Br J Cancer* 1999;81:242–51.
27. Devgan SA, Henderson BE, Yu MC, Shi CY, Pike MC, Ross RK, et al. Genetic variation of 3 beta-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: implications for prostate cancer risk. *Prostate* 1997;33:9–12.
28. Fung KM, Samara EN, Wong C, Metwalli A, Krlin R, Bane B, et al. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. *Endocr Relat Cancer* 2006;13:169–80.
29. Torres JM, Ruiz E, Ortega E. Development of a quantitative RT-PCR method to study 5alpha-reductase mRNA isozymes in rat prostate in different androgen status. *Prostate* 2003;56:74–9.
30. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. *Cancer Res* 2006;66:2815–25.
31. Steers WD. 5alpha-reductase activity in the prostate. *Urology* 2001;58:17–24.
32. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The Influence of Finasteride on the Development of Prostate Cancer. *N Engl J Med* 2003;349:215–24.
33. Gleave M, Hsieh JT, Gao CA, von Eschenbach AC, Chung LW. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. *Cancer Res* 1991;51:3753–61.
34. Hong MY, Bancroft LK, Turner ND, Davidson LA, Murphy ME, Carroll RJ, et al. Fish oil decreases oxidative DNA damage by enhancing apoptosis in rat colon. *Nutr Cancer* 2005;52:166–75.
35. Holt PR, Moss SF, Kapetanakis AM, Petrotos A, Wang S. Is Ki-67 a better proliferative marker in the colon than proliferating cell nuclear antigen? *Cancer Epidemiol Biomarkers Prev* 1997;6:131–5.
36. Hong MY, Seeram NP, Zhang Y, Heber D. Anti-cancer effects of Chinese red yeast rice versus monacolin K alone on colon cancer cells. *J Nutr Biochem* 2008;19:448–58.
37. Hall SA, Page ST, Trivison TG, Montgomery RB, Link CL, McKinlay JB. Do statins affect androgen levels in men? Results from the Boston area community health survey. *Cancer Epidemiol Biomarkers Prev* 2007;16:1587–94.
38. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. *J Clin Invest* 2005;115:959–68.
39. Solomon KR, Freeman MR. Do the cholesterol-lowering properties of statins affect cancer risk? *Trends Endocrinol Metab* 2008;19:113–21.
40. Mondul AM, Clipp SL, Helzlsouer KJ, Platz EA. Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. *Cancer Causes Control* 2010;21:61–8.
41. Pelletier G, Luu-The V, El-Alfy M, Li S, Labrie F. Immunoelectron microscopic localization of 3β-hydroxysteroid dehydrogenase and type 5 17β-hydroxysteroid dehydrogenase in the human prostate and mammary gland. *J Mol Endocrinol* 2001;26:11–9.
42. Hong MY, Seeram NP, Heber D. Pomegranate polyphenols down-regulate expression of androgen-synthesizing genes in human prostate cancer cells overexpressing the androgenreceptor. *J Nutr Biochem* 2008;19:848–55.
43. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. *Cell* 2009;138:245–56.
44. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. *Nat Rev Cancer* 2001;1:34–45.
45. Gelmann EP. Molecular biology of the androgen receptor. *J Clin Oncol* 2002;20:3001–15.
46. Grossman ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen refractory prostate cancer. *J Natl Cancer Inst* 2001;93:1687–97.
47. Graaf MR, Richel DJ, van Noorden CJ, Guchelaar HJ. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. *Cancer Treat Rev* 2004;30:609–41.
48. Mo H, Elson CE. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. *Exp Biol Med* 2004;229:567–85.
49. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. *J Clin Invest* 2005;115:959–68.
50. Liu J, Zhang J, Shi Y, Grimsgaard S, Alraek T, Fneeb V. Chinese red yeast rice (*Monascus purpureus*) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. *Chin Med*. 2006 Nov 23;1:4.
51. Venero CV, Venero JV, Wortham DC, Thompson PD. Lipid-lowering efficacy of red yeast rice in a population intolerant to statins. *Am J Cardiol* 2010;105:664–6.